《異動股》融創中國(01918.HK)跌幅擴至11%創近四年半低
內房股今天以融創中國(01918.HK)表現最差,股價跌破9月所創52周低位12.76元,報12.54元,創近四年半低,急挫11%,成交急增至8,677萬股。中國奧園(03883.HK)也跌5.5%,報2.06元。然而,萬科(02202.HK)升1.2%高見18.3元;藍籌潤地(01109.HK)及中海外(00688.HK)也升0.2%及1%分別高見33.95元及18.78元。
克而瑞發早前數據顯示,內地前「百家」地產開發商11月合同銷售金額按年降幅擴至37.6%僅7,508億元人民幣,跌幅超過10月及9月分別32.2%及36.2%。大華繼顯最新預計,內房銷售仍未見底。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.